Why the study?
Do liposomal formulations of anthracyclines reduce adverse effects, including congestive heart failure, compared to conventional anthracyclines in patients with tumors?
Population
2,220 patients with different tumors pooled from 9 randomized controlled trials
Comparison
Liposomal formulations of anthracyclines vs Conventional anthracyclines
Design
Meta-analysis
Authors
Loading...
Supports preferential liposomal anthracycline use to lower heart failure risk; confirms safety benefit in Level 1 meta-analysis.
Do liposomal formulations of anthracyclines reduce adverse effects, including congestive heart failure, compared to conventional anthracyclines in patients with tumors?
Liposomal anthracyclines demonstrate a significantly better safety profile, particularly regarding cardiotoxicity (congestive heart failure), compared to conventional anthracyclines.
Rafiyath et al. (2012) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: